Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock
投稿日:
September 21, 2016
Paris, France, September 13, 2016
Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock
Inotrem SA, a biotechnology company specializing in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers.The principal objective of this first in-man phase I clinical trial, conducted on a double-blind, randomized, placebo-controlled basis, was to evaluate Motrem’s safety, tolerance and pharmacokinetics.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
-min.jpg)
.jpg)
